Feb 27, 2017
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Feb 16, 2017
|
MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call
|
|
Feb 09, 2017
|
MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
|
|
Jan 25, 2017
|
MacroGenics Announces Appointments to Board of Directors
|
|
Jan 05, 2017
|
MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA
|
|
Jan 05, 2017
|
MacroGenics to Present at the 35th Annual J.P. Morgan Healthcare Conference
|
|
Dec 13, 2016
|
MacroGenics Highlights Progress at 2016 R&D Day
|
|
Dec 12, 2016
|
MacroGenics Licenses Synthon's Technology to Develop an Anti-B7-H3 ADC
|
|
Dec 08, 2016
|
MacroGenics to Host 2016 R&D Day
|
|
Nov 02, 2016
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2016 Financial Results
|
|
Nov 01, 2016
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Oct 26, 2016
|
MacroGenics Announces Date of Third Quarter 2016 Financial Results Conference Call
|
|
Sep 23, 2016
|
MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
|
|
Sep 20, 2016
|
MacroGenics Announces the Promotion of Three Executives
|
|
Sep 12, 2016
|
Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement
|
|
Aug 31, 2016
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Aug 04, 2016
|
MacroGenics to Participate in Two Upcoming Investor Conferences
|
|
Aug 03, 2016
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results
|
|
Jul 27, 2016
|
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call
|
|
Jun 28, 2016
|
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015
|
|
Jun 10, 2016
|
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016)
|
|
May 18, 2016
|
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for Treatment of Cancer
|
|
May 11, 2016
|
MacroGenics to Present MGD010 Clinical Data at EULAR 2016
|
|
May 10, 2016
|
First Dosing of Pfizer DART Candidate in Phase 1 Study Triggers Milestone Payment to MacroGenics
|
|
May 04, 2016
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2016 Financial Results
|
|